The Wall Street Journal: Roche to buy InterMune for $8.3 billion

Roche says it will pay $8.3 billion for a California biotech firm that has yet to turn a profit on a new drug to treat a deadly lung disease, the latest gamble by a pharmaceutical giant to buy its way into a lucrative corner of the industry.